Fulcrum Therapeutics, Inc.
FULC
$3.52
$0.082.33%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/9/2026
-
Tickeron - Stocks
6/7/2026
-
Tickeron - Stocks
6/5/2026
-
Globe Newswire
6/5/2026
-
Tickeron - Stocks
A Look At Fulcrum Therapeutics (FULC) Valuation After Halting Pociredir And Launching A Broad Review
6/4/2026
-
Simply Wall St
6/4/2026
-
TipRanks Financial Blog
6/4/2026
-
GuruFocus
6/4/2026
-
Business Wire
6/4/2026
-
Benzinga
6/4/2026
-
Tickeron - Stocks
6/4/2026
-
TipRanks Financial Blog
6/4/2026
-
Tickeron - Stocks
6/3/2026
-
Zacks Investment Research
6/3/2026
-
PR Newswire
6/3/2026
-
Tickeron - Stocks
Why Fulcrum Therapeutics (FULC) Is Down 53.6% After Ending Pociredir And Exploring Strategic Options
6/3/2026
-
Simply Wall St
6/2/2026
-
PR Newswire
6/2/2026
-
Globe Newswire
6/2/2026
-
Globe Newswire
6/2/2026
-
Zero Hedge
6/2/2026
-
FierceBiotech.com - Biotech
6/1/2026
-
Globe Newswire
5/29/2026
-
Tickeron - Stocks
5/27/2026
-
Tickeron - Stocks
5/24/2026
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, April 27, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Jul 27 and 31 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 651 8851
Address
26 Landsdowne Street
Cambridge, MA 02139
Cambridge, MA 02139
Country
Year Founded
Business Description
Sector
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet...
more